Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSLP | Q969D9 | 16/20 | 0.58 |
| ▸ | MC4R | P32245 | 4/20 | 0.50 |
| ▸ | MC1R | Q01726 | 4/20 | 0.50 |
| ▸ | MC5R | P33032 | 3/20 | 0.50 |
| ▸ | MC3R | P41968 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340729 | 0.95 | TSLP (0.58) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340671 | 0.94 | TSLP (0.57) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340418 | 0.93 | TSLP (0.56) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340575 | 0.93 | TSLP (0.56) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340684 | 0.92 | TSLP (0.57) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340572 | 0.92 | TSLP (0.58) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340904 | 0.91 | TSLP (0.56) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340382 | 0.90 | TSLP (0.56) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340903 | 0.90 | TSLP (0.54) | TSLPMC4RMC1RMC5RMC3R | |
| SCHEMBL16340843 | 0.90 | TSLP (0.53) | TSLPMC4RMC1RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | TSLP 177/4885MC4R 1/4885MC1R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.